The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematol Meeting Rep. 2009;1(2). doi:10.4081/hmr.v1i2.226